PHarmacological Audit study of Safety and Effectiveness in Real world (Phase R): Opioid for Dyspnea in Patients with Non-malignant Respiratory Diseases Study
Not Applicable
Suspended
- Conditions
- on-malignant respiratory diseases
- Registration Number
- JPRN-UMIN000049267
- Lead Sponsor
- ational Hospital Organization Kinki-Chuso Chest Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Suspended
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients who are scheduled to undergo an intervention (e.g., chest drainage of pneumothorax or pleural effusion, introduction or withdrawal of noninvasive respiratory management techniques such as NPPV or HFNC) that could cause a change in dyspnea intensity within 2 days of enrollment 2. Patients on invasive ventilation 3. Patients with malignant tumors in the thoracic cavity
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Percentage of patients with at least 1 decrease in dyspnea NRS 24 hours after initiation of regular opioid therapy
- Secondary Outcome Measures
Name Time Method Percentage of patients with dyspnea IPOS of 1 or less 24 hours after starting regular opioid therapy for dyspnea Change in dyspnea NRS (now) 24 hours after starting regular opioids for dyspnea Change in dyspnea NRS (worst value in previous 24 hours) in 24 hours after starting regular opioids for dyspnea Percentage of improvement in dyspnea by patient subjective measures 24 hours after starting regular opioids for dyspnea Opioid-related adverse events in the first 24 hours after starting regular opioids for dyspnea